US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Skye Bioscience Inc.

0.7500

-0.0230-2.98%

Post-market: 0.7481-0.0019-0.25%17:32 EDT

Volume:241.63K

Turnover:184.13K

Market Cap:25.03M

PE:-0.53

High:0.7999

Open:0.7940

Low:0.7401

Close:0.7730

52wk High:5.75

52wk Low:0.5655

Shares:33.38M

Float Shares:19.88M

Volume Ratio:1.43

T/O Rate:1.22%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-1.4100

EPS(LYR):-1.4100

ROE:-126.85%

ROA:-71.93%

PB:1.25

PE(LYR):-0.53

Loading ...

Overview Company News Filings

Skye Bioscience Inc: Skye Is Planning to Initiate a Phase 2B Clinical Trial in Obesity for Nimacimab With Enhanze in Middle of 2026

THOMSON REUTERS

Halozyme and Skye Bioscience Announce Global Collaboration and License Agreement to Evaluate Nimacimab Co-Formulated With Enhanze® for Obesity

THOMSON REUTERS

Halozyme Therapeutics Inc - Skye Plans Phase 2B Trial for Nimacimab in Mid-2026

THOMSON REUTERS

Skye Bioscience Inc - on Dec 18, Enters Collaboration Agreement With Halozyme - SEC Filing

THOMSON REUTERS

Skye Bioscience Signs Collaboration and License Agreement with Halozyme

Investors File Class Action Lawsuit Against Skye Bioscience Inc

Skye Bioscience Faces Class Action Lawsuit Over Securities Fraud Allegations

Skye Bioscience Faces Investor Class Action Over Securities Fraud Allegations

Skye Bioscience Unveils Presentation Highlighting Nimacimab’s Potential to Enhance Obesity Treatments

Skye Bioscience to Participate in Major Healthcare Investment Conferences

Skye Bioscience Showcases New Obesity Drug Data Highlighting Add-On Benefits to GLP-1 Therapies

Analysts Offer Insights on Healthcare Companies: Voyager Therapeutics (VYGR) and Skye Bioscience (SKYE)

Oppenheimer Sticks to Their Buy Rating for Skye Bioscience (SKYE)

Press Release: Skye Bioscience Reports Third Quarter 2025 Financial Results and Business Update

Analysts Offer Insights on Healthcare Companies: Skye Bioscience (SKYE) and IN8bio (INAB)

Skye Bioscience Inc expected to post a loss of 31 cents a share - Earnings Preview

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/SKYE/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SKYE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SKYE\",,,,,undefined,":{"symbol":"SKYE","market":"US","secType":"STK","nameCN":"Skye Bioscience Inc.","latestPrice":0.75,"timestamp":1776369600000,"preClose":0.773,"halted":0,"volume":241626,"hourTrading":{"tag":"盘后","latestPrice":0.7481,"preClose":0.75,"latestTime":"17:32 EDT","volume":441,"amount":333.44468639999997,"timestamp":1776375137480,"change":-0.0019,"changeRate":-0.002533,"amplitude":0.058133},"delay":0,"changeRate":-0.029754204398447632,"floatShares":19882200,"shares":33378764,"eps":-1.410011,"marketStatus":"Post-Mkt","change":-0.023,"latestTime":"04-16 17:56:41 EDT","open":0.794,"high":0.7999,"low":0.7401,"amount":184130.81301384,"amplitude":0.077361,"askPrice":0.8,"askSize":100,"bidPrice":0.73,"bidSize":107,"shortable":3,"etf":0,"ttmEps":-1.410011,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1776384000000},"marketStatusCode":4,"symbolChange":{"newSymbol":"SKYED","executeDate":"2023-09-08"},"adr":0,"exchange":"NASDAQ","adjPreClose":0.773,"preHourTrading":{"tag":"盘前","latestPrice":0.7799,"preClose":0.773,"latestTime":"09:25 EDT","volume":6156,"amount":5014.8302688,"timestamp":1776345932703,"change":0.0069,"changeRate":0.008926,"amplitude":0.051876},"postHourTrading":{"tag":"盘后","latestPrice":0.7481,"preClose":0.75,"latestTime":"17:32 EDT","volume":441,"amount":333.44468639999997,"timestamp":1776375137480,"change":-0.0019,"changeRate":-0.002533,"amplitude":0.058133},"volumeRatio":1.43152,"impliedVol":1.1162,"impliedVolPercentile":0.456},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SKYE\",,,,,undefined,":{"symbol":"SKYE","floatShares":19882200,"roa":"-71.93%","roe":"-126.85%","lyrEps":-1.410011,"volumeRatio":1.43152,"shares":33378764,"dividePrice":0,"high":0.7999,"amplitude":0.077361,"preClose":0.773,"low":0.7401,"week52Low":0.5655,"pbRate":"1.25","week52High":5.75,"institutionHeld":0,"latestPrice":0.75,"committee":0.033816,"eps":-1.410011,"divideRate":0,"volume":241626,"delay":0,"ttmEps":-1.410011,"open":0.794,"prevYearClose":0.7497,"prevWeekClose":0.72,"prevMonthClose":0.6146,"prevQuarterClose":0.6146,"fiveDayClose":0.7258,"twentyDayClose":0.6732,"sixtyDayClose":0.9729},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SKYE\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-03-10","symbol":"SKYE","fiscalQuarterEnding":"2025/12","expectedEps":-0.29,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1773115200000,"reportTimeType":"post","actualEps":-0.36},{"market":"US","date":"2025-11-10","symbol":"SKYE","fiscalQuarterEnding":"2025/09","expectedEps":-0.33,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1762750800000,"reportTimeType":"post","actualEps":-0.32},{"market":"US","date":"2025-08-07","symbol":"SKYE","fiscalQuarterEnding":"2025/06","expectedEps":-0.34,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1754539200000,"reportTimeType":"post","actualEps":-0.44},{"market":"US","date":"2025-05-08","symbol":"SKYE","fiscalQuarterEnding":"2025/03","expectedEps":-0.31,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1746676800000,"reportTimeType":"post","actualEps":-0.28},{"market":"US","date":"2025-03-20","symbol":"SKYE","fiscalQuarterEnding":"2024/12","expectedEps":-0.3,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1742443200000,"reportTimeType":"post","actualEps":-0.24}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SKYE\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SKYE\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.25,"buy":0.625,"hold":0.125,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.625,"analysts":8,"updateTime":1759809600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/SKYE\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"SKYE","date":"2026-04-15","current":-0.531911,"percent":0.915638,"low":-12.94129,"twenty":-4.536338,"median":-2.976494,"eighty":-0.819751,"high":-0.344383,"avg":-3.357823,"sd":2.592406,"marketCap":27210368},"quantilePoints":[{"date":"2024-04-12","current":-9.459964,"twenty":-9.513638,"median":-9.459964,"eighty":-7.885539,"marketCap":356118289},{"date":"2024-04-19","current":-12.650558,"twenty":-12.435864,"median":-9.657512,"eighty":-9.495746,"marketCap":476227531},{"date":"2024-04-26","current":-9.579238,"twenty":-12.081022,"median":-9.691058,"eighty":-9.561347,"marketCap":360608354},{"date":"2024-05-03","current":-9.683603,"twenty":-11.635233,"median":-9.68733,"eighty":-9.561347,"marketCap":364537161},{"date":"2024-05-10","current":-8.997775,"twenty":-10.807766,"median":-9.638876,"eighty":-9.507673,"marketCap":338719287},{"date":"2024-05-17","current":-9.168,"twenty":-10.15772,"median":-9.601602,"eighty":-9.22813,"marketCap":343770610},{"date":"2024-05-24","current":-8.952556,"twenty":-9.700003,"median":-9.54942,"eighty":-8.9931,"marketCap":335692167},{"date":"2024-05-31","current":-8.720508,"twenty":-9.691058,"median":-9.489815,"eighty":-8.983995,"marketCap":326991116},{"date":"2024-06-07","current":-8.47349,"twenty":-9.691058,"median":-9.389145,"eighty":-8.952556,"marketCap":317728707},{"date":"2024-06-14","current":-8.069277,"twenty":-9.691058,"median":-9.18753,"eighty":-8.690567,"marketCap":302572037},{"date":"2024-06-21","current":-6.684476,"twenty":-9.685094,"median":-9.060284,"eighty":-8.473188,"marketCap":250646409},{"date":"2024-06-28","current":-5.434411,"twenty":-9.674658,"median":-9.022864,"eighty":-8.245631,"marketCap":203773004},{"date":"2024-07-05","current":-5.58412,"twenty":-9.638876,"median":-8.993879,"eighty":-7.844715,"marketCap":209386586},{"date":"2024-07-12","current":-4.873005,"twenty":-9.631421,"median":-8.980898,"eighty":-7.11863,"marketCap":182722074},{"date":"2024-07-15","current":-4.820607,"twenty":-9.62993,"median":-8.974213,"eighty":-6.892464,"marketCap":180757321},{"date":"2024-08-02","current":-4.102007,"twenty":-9.628439,"median":-8.967527,"eighty":-6.745055,"marketCap":153812130},{"date":"2024-08-09","current":-3.735222,"twenty":-9.606075,"median":-8.870216,"eighty":-5.58412,"marketCap":140058855},{"date":"2024-08-16","current":-3.615791,"twenty":-9.579238,"median":-8.690567,"eighty":-4.690361,"marketCap":152904981},{"date":"2024-08-23","current":-3.787972,"twenty":-9.567311,"median":-8.506414,"eighty":-4.17237,"marketCap":160186171},{"date":"2024-08-30","current":-4.584307,"twenty":-9.543456,"median":-8.189044,"eighty":-4.185844,"marketCap":193861673},{"date":"2024-09-06","current":-4.347559,"twenty":-9.525571,"median":-8.069277,"eighty":-4.204574,"marketCap":183850037},{"date":"2024-09-13","current":-4.304513,"twenty":-9.489808,"median":-7.545298,"eighty":-4.204574,"marketCap":182029740},{"date":"2024-09-20","current":-3.93863,"twenty":-9.483818,"median":-7.11863,"eighty":-4.170873,"marketCap":166557212},{"date":"2024-09-27","current":-2.840979,"twenty":-9.431636,"median":-6.35886,"eighty":-4.072065,"marketCap":120139628},{"date":"2024-10-04","current":-2.56836,"twenty":-9.296072,"median":-5.58412,"eighty":-3.802872,"marketCap":108611078},{"date":"2024-10-11","current":-2.683147,"twenty":-9.199248,"median":-5.224584,"eighty":-3.740033,"marketCap":113465204},{"date":"2024-10-18","current":-3.034682,"twenty":-9.153032,"median":-4.873005,"eighty":-3.308736,"marketCap":128330966},{"date":"2024-10-25","current":-3.501004,"twenty":-9.080009,"median":-4.593919,"eighty":-3.325954,"marketCap":148050855},{"date":"2024-10-31","current":-3.651662,"twenty":-9.02741,"median":-4.557114,"eighty":-3.343172,"marketCap":154421896},{"date":"2024-11-08","current":-7.770049,"twenty":-9.018318,"median":-4.55561,"eighty":-3.379043,"marketCap":165040297},{"date":"2024-11-15","current":-7.870031,"twenty":-8.997775,"median":-4.571462,"eighty":-3.501004,"marketCap":167163977},{"date":"2024-11-22","current":-5.956085,"twenty":-8.989983,"median":-4.820607,"eighty":-3.501004,"marketCap":126510669},{"date":"2024-11-29","current":-6.413147,"twenty":-8.983995,"median":-4.921494,"eighty":-3.53544,"marketCap":136218922},{"date":"2024-12-06","current":-5.070528,"twenty":-8.981218,"median":-5.25247,"eighty":-3.595703,"marketCap":107700929},{"date":"2024-12-13","current":-4.784865,"twenty":-8.970201,"median":-5.21336,"eighty":-3.614356,"marketCap":101633271},{"date":"2024-12-20","current":-4.084989,"twenty":-8.95555,"median":-5.042643,"eighty":-3.644488,"marketCap":86767509},{"date":"2024-12-27","current":-3.799325,"twenty":-8.952556,"median":-4.89725,"eighty":-3.64221,"marketCap":80699851},{"date":"2025-01-03","current":-4.070706,"twenty":-8.886684,"median":-4.82416,"eighty":-3.64221,"marketCap":86464126},{"date":"2025-01-10","current":-4.427785,"twenty":-8.774403,"median":-4.734873,"eighty":-3.64221,"marketCap":94048699},{"date":"2025-01-17","current":-3.856458,"twenty":-8.71452,"median":-4.60353,"eighty":-3.6441,"marketCap":81913383},{"date":"2025-01-24","current":-3.727909,"twenty":-8.690567,"median":-4.558618,"eighty":-3.651662,"marketCap":79182936},{"date":"2025-01-31","current":-5.356192,"twenty":-8.660625,"median":-4.557114,"eighty":-3.694707,"marketCap":113768587},{"date":"2025-02-07","current":-4.256387,"twenty":-8.539337,"median":-4.55561,"eighty":-3.699343,"marketCap":90408104},{"date":"2025-02-14","current":-4.370652,"twenty":-8.47349,"median":-4.466458,"eighty":-3.699343,"marketCap":92835167},{"date":"2025-02-21","current":-4.470635,"twenty":-8.472282,"median":-4.477777,"eighty":-3.722196,"marketCap":94958847},{"date":"2025-02-28","current":-3.827892,"twenty":-8.245631,"median":-4.442068,"eighty":-3.730044,"marketCap":81306617},{"date":"2025-03-07","current":-3.670777,"twenty":-8.162365,"median":-4.40636,"eighty":-3.699343,"marketCap":77969405},{"date":"2025-03-14","current":-3.463671,"twenty":-8.134468,"median":-4.354733,"eighty":-3.698416,"marketCap":73570353},{"date":"2025-03-21","current":-2.203547,"twenty":-8.081254,"median":-4.304513,"eighty":-3.649772,"marketCap":58541914},{"date":"2025-03-28","current":-2.471704,"twenty":-7.90988,"median":-4.297339,"eighty":-3.6255,"marketCap":65666062},{"date":"2025-04-04","current":-1.632257,"twenty":-7.858605,"median":-4.256387,"eighty":-3.582221,"marketCap":43364381},{"date":"2025-04-11","current":-1.562303,"twenty":-7.846922,"median":-4.225597,"eighty":-3.501004,"marketCap":41505907},{"date":"2025-04-17","current":-1.842119,"twenty":-7.799915,"median":-4.189726,"eighty":-3.364695,"marketCap":48939801},{"date":"2025-04-25","current":-2.086958,"twenty":-7.727199,"median":-4.165203,"eighty":-3.259602,"marketCap":55444458},{"date":"2025-05-02","current":-2.366773,"twenty":-7.630073,"median":-4.156405,"eighty":-3.056205,"marketCap":62878352},{"date":"2025-05-09","current":-1.698098,"twenty":-7.560926,"median":-4.127838,"eighty":-2.911286,"marketCap":55444458},{"date":"2025-05-16","current":-1.907406,"twenty":-7.545298,"median":-4.116978,"eighty":-2.799369,"marketCap":62278559},{"date":"2025-05-23","current":-1.964344,"twenty":-7.500386,"median":-4.077848,"eighty":-2.746856,"marketCap":64137621},{"date":"2025-05-30","current":-2.011792,"twenty":-7.329718,"median":-4.070706,"eighty":-2.683147,"marketCap":65686838},{"date":"2025-06-06","current":-2.040261,"twenty":-7.099247,"median":-4.06458,"eighty":-2.616276,"marketCap":66616369},{"date":"2025-06-13","current":-2.05924,"twenty":-6.976473,"median":-4.013573,"eighty":-2.54373,"marketCap":67236056},{"date":"2025-06-20","current":-2.030771,"twenty":-6.805634,"median":-3.979786,"eighty":-2.387759,"marketCap":66306526},{"date":"2025-06-27","current":-4.033073,"twenty":-6.650207,"median":-3.970723,"eighty":-2.387759,"marketCap":131683521},{"date":"2025-07-03","current":-4.374698,"twenty":-6.513129,"median":-3.970723,"eighty":-2.471704,"marketCap":142837890},{"date":"2025-07-11","current":-3.738896,"twenty":-6.413147,"median":-3.970723,"eighty":-2.503792,"marketCap":122078370},{"date":"2025-07-18","current":-3.530125,"twenty":-6.413147,"median":-3.966646,"eighty":-2.541658,"marketCap":115261811},{"date":"2025-07-25","current":-3.805323,"twenty":-6.298881,"median":-3.947535,"eighty":-2.546837,"marketCap":124247275},{"date":"2025-08-01","current":-3.387782,"twenty":-6.198899,"median":-3.902759,"eighty":-2.561185,"marketCap":110614158},{"date":"2025-08-08","current":-3.368802,"twenty":-6.1132,"median":-3.885025,"eighty":-2.56836,"marketCap":109994470},{"date":"2025-08-15","current":-2.391434,"twenty":-6.1132,"median":-3.856458,"eighty":-2.546837,"marketCap":101332133},{"date":"2025-08-22","current":-2.596205,"twenty":-6.1132,"median":-3.856458,"eighty":-2.541658,"marketCap":110008891},{"date":"2025-08-29","current":-2.545012,"twenty":-6.033244,"median":-3.838191,"eighty":-2.530385,"marketCap":107839701},{"date":"2025-09-05","current":-2.74247,"twenty":-6.003302,"median":-3.805323,"eighty":-2.498872,"marketCap":116206575},{"date":"2025-09-12","current":-3.115445,"twenty":-5.964031,"median":-3.793648,"eighty":-2.525066,"marketCap":132010669},{"date":"2025-09-19","current":-2.881421,"twenty":-5.898952,"median":-3.776855,"eighty":-2.539403,"marketCap":122094374},{"date":"2025-09-26","current":-2.632771,"twenty":-5.861816,"median":-3.757875,"eighty":-2.544341,"marketCap":111558312},{"date":"2025-10-03","current":-3.28365,"twenty":-5.684705,"median":-3.738896,"eighty":-2.546472,"marketCap":139138005},{"date":"2025-10-10","current":-1.257879,"twenty":-5.595667,"median":-3.729992,"eighty":-2.525066,"marketCap":53300082},{"date":"2025-10-17","current":-1.060422,"twenty":-5.58412,"median":-3.727909,"eighty":-2.468814,"marketCap":44933209},{"date":"2025-10-24","current":-1.060422,"twenty":-5.516043,"median":-3.699343,"eighty":-2.388509,"marketCap":44933209},{"date":"2025-10-31","current":-1.075048,"twenty":-5.447334,"median":-3.691448,"eighty":-2.317303,"marketCap":45552977},{"date":"2025-11-07","current":-1.111614,"twenty":-5.371836,"median":-3.676368,"eighty":-2.244599,"marketCap":47102398},{"date":"2025-11-14","current":-0.828708,"twenty":-5.321912,"median":-3.651662,"eighty":-2.178806,"marketCap":42454135},{"date":"2025-11-21","current":-0.782205,"twenty":-5.233356,"median":-3.64221,"eighty":-2.124921,"marketCap":40071826},{"date":"2025-11-28","current":-0.819751,"twenty":-5.18765,"median":-3.621859,"eighty":-2.093402,"marketCap":41995273},{"date":"2025-12-05","current":-0.757174,"twenty":-5.110521,"median":-3.608617,"eighty":-2.055444,"marketCap":38789527},{"date":"2025-12-12","current":-0.719628,"twenty":-5.037066,"median":-3.577936,"eighty":-2.025264,"marketCap":36866080},{"date":"2025-12-19","current":-0.625701,"twenty":-4.9588,"median":-3.549105,"eighty":-1.981949,"marketCap":32054255},{"date":"2025-12-26","current":-0.522137,"twenty":-4.912548,"median":-3.544049,"eighty":-1.945365,"marketCap":26748745},{"date":"2026-01-02","current":-0.469135,"twenty":-4.89913,"median":-3.530125,"eighty":-1.880836,"marketCap":24033478},{"date":"2026-01-09","current":-0.657052,"twenty":-4.893905,"median":-3.501657,"eighty":-1.841207,"marketCap":33660334},{"date":"2026-01-16","current":-0.60236,"twenty":-4.863947,"median":-3.501004,"eighty":-1.780246,"marketCap":30858511},{"date":"2026-01-23","current":-0.657052,"twenty":-4.827714,"median":-3.463671,"eighty":-1.698098,"marketCap":33660334},{"date":"2026-01-30","current":-0.600733,"twenty":-4.820607,"median":-3.430485,"eighty":-1.632257,"marketCap":30775162},{"date":"2026-02-06","current":-0.500298,"twenty":-4.784865,"median":-3.387782,"eighty":-1.562303,"marketCap":25629940},{"date":"2026-02-13","current":-0.451176,"twenty":-4.684882,"median":-3.355987,"eighty":-1.389518,"marketCap":23113429},{"date":"2026-02-20","current":-0.488221,"twenty":-4.650603,"median":-3.310888,"eighty":-1.249103,"marketCap":25011231},{"date":"2026-02-27","current":-0.482464,"twenty":-4.611231,"median":-3.270848,"eighty":-1.139404,"marketCap":24716302},{"date":"2026-03-06","current":-0.461814,"twenty":-4.588626,"median":-3.232166,"eighty":-1.117465,"marketCap":23658406},{"date":"2026-03-13","current":-0.421973,"twenty":-4.584426,"median":-3.115445,"eighty":-1.099913,"marketCap":23598786},{"date":"2026-03-20","current":-0.391057,"twenty":-4.563756,"median":-3.07414,"eighty":-1.060422,"marketCap":21869766},{"date":"2026-03-27","current":-0.368854,"twenty":-4.556212,"median":-3.020373,"eighty":-1.032631,"marketCap":20628076},{"date":"2026-04-02","current":-0.396846,"twenty":-4.55561,"median":-3.01306,"eighty":-0.904924,"marketCap":22193540},{"date":"2026-04-10","current":-0.433194,"twenty":-4.547475,"median":-2.991518,"eighty":-0.825125,"marketCap":24226306},{"date":"2026-04-15","current":-0.486553,"twenty":-4.536338,"median":-2.976494,"eighty":-0.819751,"marketCap":27210368}],"updateTime":1776376601201},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SKYE\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2601885098","title":"Skye Bioscience Inc:  Skye Is Planning to Initiate a Phase 2B Clinical Trial in Obesity for Nimacimab With Enhanze in Middle of 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2601885098","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601885098?lang=en_us&edition=fundamental","pubTime":"2026-01-05 20:00","pubTimestamp":1767614418,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nFWN3Y60HA:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["HALO","SKYE","LU0053671581.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2601885793","title":"Halozyme and Skye Bioscience Announce Global Collaboration and License Agreement to Evaluate Nimacimab Co-Formulated With Enhanze® for Obesity","url":"https://stock-news.laohu8.com/highlight/detail?id=2601885793","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601885793?lang=en_us&edition=fundamental","pubTime":"2026-01-05 20:00","pubTimestamp":1767614403,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nTUA2R2D2B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["HALO","BK4139","LU0053671581.USD","SKYE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2601588503","title":"Halozyme Therapeutics Inc - Skye Plans Phase 2B Trial for Nimacimab in Mid-2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2601588503","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601588503?lang=en_us&edition=fundamental","pubTime":"2026-01-05 20:00","pubTimestamp":1767614403,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nTUA2R2D2B:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["HALO","BK4139","LU0053671581.USD","SKYE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2593448072","title":"Skye Bioscience Inc - on Dec 18, Enters Collaboration Agreement With Halozyme - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2593448072","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593448072?lang=en_us&edition=fundamental","pubTime":"2025-12-24 05:07","pubTimestamp":1766524025,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251223:nFWN3XT0P9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SKYE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2593544806","title":"Skye Bioscience Signs Collaboration and License Agreement with Halozyme","url":"https://stock-news.laohu8.com/highlight/detail?id=2593544806","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593544806?lang=en_us&edition=fundamental","pubTime":"2025-12-24 05:05","pubTimestamp":1766523910,"startTime":"0","endTime":"0","summary":"Skye Bioscience Inc. announced that it has entered into a Non-exclusive Collaboration and License Agreement with Halozyme, Inc. Under the agreement, Skye Bioscience will receive a non-exclusive license to Halozyme's ENHANZE drug delivery technology for the development of a subcutaneous formulation of nimacimab. Halozyme will be the exclusive supplier of clinical and commercial supplies of the rHuPH20 bulk drug product for Skye Bioscience. The agreement includes milestone payments tied to development and commercialization events, as well as royalty payments based on worldwide net sales of the product.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Skye Bioscience Inc. published the original content used to generate this news brief via E","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251223:nNDL2qfW9V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SKYE","LU0053671581.USD","BK4139","HALO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2593041068","title":"Investors File Class Action Lawsuit Against Skye Bioscience Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2593041068","media":"Reuters","labels":["policyRegulatory","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593041068?lang=en_us&edition=fundamental","pubTime":"2025-12-24 03:42","pubTimestamp":1766518942,"startTime":"0","endTime":"0","summary":"A class action lawsuit has been filed against Skye Bioscience Inc. on behalf of investors who suffered losses due to alleged securities fraud between November 4, 2024, and October 3, 2025. The case is being handled by the law firm Levi & Korsinsky, which has a history of representing shareholders in complex securities litigation. Investors affected during the specified period are encouraged to seek information about their rights and potential recovery options.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Skye Bioscience Inc. published the original content used to generate this news brief via ACCESS Newswire  on December 23, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251223:nNDL95n2z3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SKYE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2592194201","title":"Skye Bioscience Faces Class Action Lawsuit Over Securities Fraud Allegations","url":"https://stock-news.laohu8.com/highlight/detail?id=2592194201","media":"Reuters","labels":["policyRegulatory","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592194201?lang=en_us&edition=fundamental","pubTime":"2025-12-20 03:42","pubTimestamp":1766173336,"startTime":"0","endTime":"0","summary":"A class action lawsuit has been filed against Skye Bioscience Inc., alleging securities fraud that affected investors between November 4, 2024, and October 3, 2025. The lawsuit claims that shareholders suffered financial losses as a result of the company’s actions during this period. Investors who experienced losses are encouraged to seek information about their legal rights and potential remedies. The case is being handled by the law firm Levi & Korsinsky, which has a significant track record in securities litigation.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Skye Bioscience Inc. published the original content used to generate this news brief via ACCESS Newswire  on December 19, 2025, and is solely responsible for the information","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251219:nNDL8HQNBx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SKYE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2590537288","title":"Skye Bioscience Faces Investor Class Action Over Securities Fraud Allegations","url":"https://stock-news.laohu8.com/highlight/detail?id=2590537288","media":"Reuters","labels":["policyRegulatory","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590537288?lang=en_us&edition=fundamental","pubTime":"2025-12-11 03:47","pubTimestamp":1765396037,"startTime":"0","endTime":"0","summary":"A class action lawsuit has been filed against Skye Bioscience Inc., alleging securities fraud that affected investors who purchased shares between November 4, 2024, and October 3, 2025. The legal action claims that shareholders suffered financial losses due to the company's alleged misconduct. The case is being handled by the law firm Levi & Korsinsky, which has a history of representing investors in securities litigation and has secured significant recoveries for clients in previous cases. Investors who suffered losses during the specified period are encouraged to seek information about their rights and potential participation in the lawsuit.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Skye Bioscience Inc. published the original co","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nNDL6Q2QZj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SKYE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2585461547","title":"Skye Bioscience Unveils Presentation Highlighting Nimacimab’s Potential to Enhance Obesity Treatments","url":"https://stock-news.laohu8.com/highlight/detail?id=2585461547","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585461547?lang=en_us&edition=fundamental","pubTime":"2025-11-24 20:04","pubTimestamp":1763985851,"startTime":"0","endTime":"0","summary":"Skye Bioscience Inc. has provided an update on the development of nimacimab, a novel therapeutic candidate for obesity and metabolic diseases. According to the presentation, nimacimab is positioned as a complementary treatment to existing GLP-1 therapies, offering approximately 3% additional weight loss when used in combination with semaglutide over 26 weeks. The data also indicate a lower rate of post-treatment weight rebound and a favorable body composition profile compared to GLP-1 monotherapy. The company highlights nimacimab's differentiated peripheral CB1 mechanism, which does not increase gastrointestinal or neuropsychiatric adverse events in combination regimens. Skye Bioscience reports a clear pharmacokinetic and exposure-response profile from Phase 2a studies and is planning further evaluation at higher doses. Nimacimab is presented as suitable for both patients who do not respond to or tolerate GLP-1 therapies and for those seeking enhanced weight loss outcomes. You can acce","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nNDL8JPPYQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SKYE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2585615834","title":"Skye Bioscience to Participate in Major Healthcare Investment Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2585615834","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585615834?lang=en_us&edition=fundamental","pubTime":"2025-11-24 20:01","pubTimestamp":1763985661,"startTime":"0","endTime":"0","summary":"Skye Bioscience Inc. will participate in several upcoming investment conferences, including the Citi Global Healthcare Conference in Miami with 1x1 meetings on December 2, the Evercore Annual Healthcare Conference in Coral Gables featuring a fireside chat on December 3 at 12:55 pm ET and 1x1 meetings, and the Piper Sandler Annual Healthcare Conference in New York with a fireside chat on December 4 at 11:30 am ET and 1x1 meetings. Webcasts of the events will be available on Skye's website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Skye Bioscience Inc. published the original content used to generate this news brief via Newsfile  on November 24, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nNDLbnvhXW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0130102774.USD","LU1244550494.USD","PIPR","BK4127","LU1366192091.USD","LU1668664300.SGD","BK4504","LU1267930227.SGD","LU0072461881.USD","LU2462157665.USD","LU1201861249.SGD","LU0106831901.USD","BK4207","EVR","LU0320765646.SGD","LU0980610538.SGD","LU2236285917.USD","LU0128525689.USD","LU0648001328.SGD","BK4585","LU1244550577.SGD","BK4139","SKYE","LU0130517989.USD","LU1244550221.USD","BK4559","LU0162691827.USD","LU1791807156.HKD","LU2417539215.USD","BK4534","LU2125154778.USD","BK4566","LU0052756011.USD","LU0310800965.SGD","IE00BSNM7G36.USD","LU0477156953.USD","LU2360032135.SGD","BK4588","LU1162221912.USD","LU2456880835.USD","LU0170899867.USD","LU2125154935.USD","LU0098860793.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2584901102","title":"Skye Bioscience Showcases New Obesity Drug Data Highlighting Add-On Benefits to GLP-1 Therapies","url":"https://stock-news.laohu8.com/highlight/detail?id=2584901102","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584901102?lang=en_us&edition=fundamental","pubTime":"2025-11-20 12:01","pubTimestamp":1763611294,"startTime":"0","endTime":"0","summary":"Skye Bioscience Inc. has highlighted new data on its investigational obesity treatment, nimacimab, in a recent corporate presentation. According to the company, nimacimab is designed to complement existing GLP-1 therapies, providing approximately 3% additional weight loss over semaglutide alone at 26 weeks, with continued benefit over time. The presentation notes that nimacimab may offer more durable weight loss, with a lower post-treatment rebound rate and a favorable body-composition profile compared to GLP-1 monotherapy. The combination of nimacimab with incretin therapies was reported to show no increase in gastrointestinal side effects or neuropsychiatric adverse events. Skye Bioscience positions nimacimab as a differentiated, combination-friendly option with a peripheral CB1 mechanism, targeting both GLP-1 non-responders and those seeking enhanced weight loss outcomes. The company also reported a clear pharmacokinetic and exposure-response understanding from Phase 2a trials, supp","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251120:nNDL4DtPlJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SKYE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2583303159","title":"Analysts Offer Insights on Healthcare Companies: Voyager Therapeutics (VYGR) and Skye Bioscience (SKYE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2583303159","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583303159?lang=en_us&edition=fundamental","pubTime":"2025-11-12 23:50","pubTimestamp":1762962610,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Voyager Therapeutics (VYGR – Research Report) and Skye Bioscience...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-voyager-therapeutics-vygr-and-skye-bioscience-skye-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-voyager-therapeutics-vygr-and-skye-bioscience-skye-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","SKYE","BK4588","XLV","HCSG","LU0029874061.USD","BK4585","BK4581","LABU","VYGR","XBI","LU0128526141.USD","BK4137"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2582237960","title":"Oppenheimer Sticks to Their Buy Rating for Skye Bioscience (SKYE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2582237960","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582237960?lang=en_us&edition=fundamental","pubTime":"2025-11-12 20:57","pubTimestamp":1762952221,"startTime":"0","endTime":"0","summary":"In a report released today, Jay Olson from Oppenheimer maintained a Buy rating on Skye Bioscience, with a price target of $10.00. According to TipR...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/oppenheimer-sticks-to-their-buy-rating-for-skye-bioscience-skye-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/oppenheimer-sticks-to-their-buy-rating-for-skye-bioscience-skye-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SKYE","OPY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2582807498","title":"Press Release: Skye Bioscience Reports Third Quarter 2025 Financial Results and Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2582807498","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582807498?lang=en_us&edition=fundamental","pubTime":"2025-11-11 05:01","pubTimestamp":1762808460,"startTime":"0","endTime":"0","summary":"-- Topline nimacimab Phase 2a study data showed clinically meaningful weight. after 26 weeks of treatment; the data demonstrated a clean. neuropsychiatric safety profile and no increase in gastrointestinal. -- Nimacimab plus semaglutide showed additional reduction in waist. period in patients treated with nimacimab plus semaglutide vs.\"As we obtain additional data from our CBeyond Phase 2a study, a holistic review provides us with additional confidence that nimacimab's biology is active and has the potential to fill notable gaps in the obesity and overweight landscape in order to support a healthier weight loss journey for patients,\" said Punit Dhillon, President & CEO of Skye. \"With the positive combination data, we are shifting our focus to a combination development pathway while simultaneously planning to further understand nimacimab's potential benefit in a monotherapy setting. We anticipate that forthcoming biomarker data and the readout from the 26-week extension will continue to","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4232","BK4139","BK4099","BK4022","03160","TM","R","BK4604","BK4555","BK4588","SKYE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2581832638","title":"Analysts Offer Insights on Healthcare Companies: Skye Bioscience (SKYE) and IN8bio (INAB)","url":"https://stock-news.laohu8.com/highlight/detail?id=2581832638","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581832638?lang=en_us&edition=fundamental","pubTime":"2025-11-08 06:10","pubTimestamp":1762553411,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Skye Bioscience (SKYE – Research Report) and IN8bio ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-skye-bioscience-skye-and-in8bio-inab-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-skye-bioscience-skye-and-in8bio-inab-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XLV","BK4581","BK4588","LU0128526141.USD","INAB","BK4539","LU0029874061.USD","BK4137","BK4139","LABU","SKYE","XBI","HCSG","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2580294221","title":"Skye Bioscience Inc  expected to post a loss of 31 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2580294221","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580294221?lang=en_us&edition=fundamental","pubTime":"2025-11-03 19:34","pubTimestamp":1762169656,"startTime":"0","endTime":"0","summary":"Skye Bioscience Inc  expected to post a loss of31cents a share - Earnings Preview Skye Bioscience Inc SKYE.OQ SKYE.O is expected to  show no change in quarterly revenue when it reports  results on Nov","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251103:nL8N3WF0R9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SKYE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":3,"totalSize":56,"code":"91000000","status":"200"}]}}